FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKThe FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by Share XFDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKhttps://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/
COPD: the world’s biggest neglected disease?We speak to Verona Pharma’s CEO Jan-Anders Karlsson to find out how the company is looking to tackle Share XCOPD: the world’s biggest neglected disease?https://pharmaphorum.com/r-d/views-analysis-r-d/copd-the-worlds-biggest-neglected-disease/
AZ sees triple approval in Japan for cancer and COPD drugsAstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its Share XAZ sees triple approval in Japan for cancer and COPD drugshttps://pharmaphorum.com/news/az-sees-triple-approval-in-japan-lynparza/
Novartis builds case for asthma drugs to challenge GSKNovartis has positive data for a two-drug asthma regimen that forms the backbone of its efforts to take Share XNovartis builds case for asthma drugs to challenge GSKhttps://pharmaphorum.com/news/novartis-asthma-drugs-challenge-gsk/
Boehringer looks to enhance COPD care with new registryBoehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience Share XBoehringer looks to enhance COPD care with new registryhttps://pharmaphorum.com/news/boehringer-enhance-copd-care-new-registry/
Study aims to identify digital predictors of COPD exacerbationsSpire Health has launched a research study on COPD exacerbations using continuous respiratory sensors to assess adherence and Share XStudy aims to identify digital predictors of COPD exacerbationshttps://pharmaphorum.com/news/study-aims-to-identify-digital-predictors-of-copd-exacerbations/
Mylan launches Advair generic at 70% discount in USMylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the Share XMylan launches Advair generic at 70% discount in UShttps://pharmaphorum.com/news/mylan-launches-advair-generic-at-70-discount-in-us/
AZ’s new COPD inhaler Bevespi Aerosphere approved in EUAstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic Share XAZ’s new COPD inhaler Bevespi Aerosphere approved in EUhttps://pharmaphorum.com/news/astrazeneca-copd-bevespi-aerosphere/
AZ COPD drug fails to match GSK rival after disappointing launchAstraZeneca has said it is analysing “inconsistent” results after a late-stage trial of its Bevespi Aerosphere inhaler in Share XAZ COPD drug fails to match GSK rival after disappointing launchhttps://pharmaphorum.com/news/az-copd-drug-fails-match-gsk-rival/
